Jackson M - Search Results

1

The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Treseder SA, Jackson M, Jenner P. Treseder SA, et al. Among authors: jackson m. Br J Pharmacol. 2000 Apr;129(7):1355-64. doi: 10.1038/sj.bjp.0703189. Br J Pharmacol. 2000. PMID: 10742291 Free PMC article.

2

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Pearce RK, et al. Among authors: jackson m. Mov Disord. 1995 Nov;10(6):731-40. doi: 10.1002/mds.870100606. Mov Disord. 1995. PMID: 8749992

3

Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.

Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Mackenzie GM, et al. Among authors: jackson mj. Synapse. 1997 Jul;26(3):301-16. doi: 10.1002/(SICI)1098-2396(199707)26:3<301::AID-SYN11>3.0.CO;2-Y. Synapse. 1997. PMID: 9183819

4

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.

Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Kanda T, et al. Among authors: jackson mj. Ann Neurol. 1998 Apr;43(4):507-13. doi: 10.1002/ana.410430415. Ann Neurol. 1998. PMID: 9546333

5

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.

Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD. Pearce RK, et al. Among authors: jackson m. Psychopharmacology (Berl). 1999 Feb;142(1):51-60. doi: 10.1007/s002130050861. Psychopharmacology (Berl). 1999. PMID: 10102782

6

Antiparkinsonian activity of adenosine A2A antagonists in experimental models.

Kuwana Y, Shiozaki S, Kanda T, Kurokawa M, Koga K, Ochi M, Ikeda K, Kase H, Jackson MJ, Smith LA, Pearce RK, Jenner PG. Kuwana Y, et al. Among authors: jackson mj. Adv Neurol. 1999;80:121-3. Adv Neurol. 1999. PMID: 10410710 Review. No abstract available.

7

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Kanda T, et al. Among authors: jackson mj. Exp Neurol. 2000 Apr;162(2):321-7. doi: 10.1006/exnr.2000.7350. Exp Neurol. 2000. PMID: 10739638

8

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.

Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RK, Jenner P. Iravani MM, et al. Among authors: jackson mj. Eur J Neurosci. 2001 Feb;13(3):597-608. doi: 10.1046/j.1460-9568.2001.01408.x. Eur J Neurosci. 2001. PMID: 11168568

9

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

Maratos EC, Jackson MJ, Pearce RK, Jenner P. Maratos EC, et al. Among authors: jackson mj. Mov Disord. 2001 Jul;16(4):631-41. doi: 10.1002/mds.1149. Mov Disord. 2001. PMID: 11481686

10

The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.

Smith LA, Jackson MJ, Al-Barghouthy G, Jenner P. Smith LA, et al. Among authors: jackson mj. J Neural Transm (Vienna). 2002 Feb;109(2):123-40. doi: 10.1007/s007020200009. J Neural Transm (Vienna). 2002. PMID: 12075853

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,159 results

Search Page

Filters